Education
About Us
Working with TipRanks
Follow Us
XORTX Therapeutics Inc (XRTX)
NASDAQ:XRTX
XRTX Stock Chart & Stats
$0.58
-$0.02(-1.68%)
At close: 4:00 PM EST
$0.58
-$0.02(-1.68%)
Day’s Range― - ―
52-Week Range$0.37 - $1.41
Previous CloseN/A
Volume19.17K
Average Volume (3M)3.79M
Market Cap
$3.08M
Enterprise Value$541.79K
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$51.11K
Price to Earnings (P/E)―
Beta0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,962,218
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.78
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces solvency and interest expense risks, preserving financial flexibility for an early-stage biotech. This structural low-leverage profile supports the company’s ability to fund clinical programs via equity or partnerships without immediate debt servicing pressures.
Moderating Cash BurnA measurable improvement in free cash flow over several years signals durable progress in reducing operating outflows. Sustained lower burn improves runway and reduces the cadence and size of external financings, supporting longer-term program continuity and strategic options.
Focused PipelineA concentrated R&D focus on oxypurinol for progressive kidney diseases targets a clear unmet medical need. This specialization can create clinical expertise, streamline development priorities, and improve prospects for partnerships or licensing if pivotal data validate the approach.
Bears Say
No Revenue / Ongoing LossesThe absence of any revenue and persistent operating losses mean the company remains fully pre-revenue and reliant on capital markets. Over the medium term this constrains reinvestment, increases dilution risk from future financings, and limits self-sustainability until commercial revenues materialize.
Negative Cash FlowConsistent negative operating and free cash flows create an ongoing need for external funding. This structural dependence increases execution risk: funding delays or adverse financing terms can slow trials, force program cuts, or trigger dilutive capital raises that impact long-term shareholder value.
Erosion Of Equity BaseMaterial decline in shareholders' equity over several years erodes the balance sheet cushion and resilience to setbacks. A weakened equity base reduces flexibility to absorb trial overruns or delays and makes the company more likely to seek dilutive financings or strategic transactions to sustain development.
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $0.37 and its highest was $1.41 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.08M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XORTX Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 6,962,218 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Ownership Overview
Options Prices
Currently, No data available
---